{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=63",
    "query": {
      "condition": "Lymphoma",
      "page": 63
    },
    "page_size": 10
  },
  "pagination": {
    "page": 63,
    "page_size": 10,
    "total_count": 5758,
    "total_pages": 576,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=64&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=62&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T06:51:48.530Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01035463",
      "title": "Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Large Cell Lymphoma, ALK-Negative",
        "Recurrent Anaplastic Large Cell Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Transformed Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2009-11-12",
      "completion_date": "2018-07-27",
      "has_results": true,
      "last_update_posted_date": "2023-10-10",
      "last_synced_at": "2026-10-31T06:51:48.530Z",
      "location_count": 3,
      "location_summary": "Westwood, Kansas • Omaha, Nebraska • Cleveland, Ohio",
      "locations": [
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01035463"
    },
    {
      "nct_id": "NCT02348216",
      "title": "Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Refractory Diffuse Large B Cell Lymphoma (DLBCL)",
        "Relapsed Diffuse Large B-Cell Lymphoma",
        "Transformed Follicular Lymphoma (TFL)",
        "Primary Mediastinal B-cell Lymphoma (PMBCL)",
        "High Grade B-cell Lymphoma (HGBCL)"
      ],
      "interventions": [
        {
          "name": "Axicabtagene Ciloleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Levetiracetam",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "High-dose methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 307,
      "start_date": "2015-04-21",
      "completion_date": "2023-07-27",
      "has_results": true,
      "last_update_posted_date": "2024-06-04",
      "last_synced_at": "2026-10-31T06:51:48.530Z",
      "location_count": 23,
      "location_summary": "Gilbert, Arizona • Duarte, California • La Jolla, California + 19 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02348216"
    },
    {
      "nct_id": "NCT00377104",
      "title": "Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-cell Chronic Lymphocytic Leukemia",
        "Contiguous Stage II Small Lymphocytic Lymphoma",
        "Noncontiguous Stage II Small Lymphocytic Lymphoma",
        "Stage I Chronic Lymphocytic Leukemia",
        "Stage I Small Lymphocytic Lymphoma",
        "Stage II Chronic Lymphocytic Leukemia",
        "Stage III Chronic Lymphocytic Leukemia",
        "Stage III Small Lymphocytic Lymphoma",
        "Stage IV Chronic Lymphocytic Leukemia",
        "Stage IV Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "alvocidib",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2006-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-07-02",
      "last_synced_at": "2026-10-31T06:51:48.530Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00377104"
    },
    {
      "nct_id": "NCT05918809",
      "title": "Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1031,
      "start_date": "2021-07-25",
      "completion_date": "2022-06-17",
      "has_results": false,
      "last_update_posted_date": "2023-06-26",
      "last_synced_at": "2026-10-31T06:51:48.530Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05918809"
    },
    {
      "nct_id": "NCT01693614",
      "title": "Safety and Efficacy of BKM120 in Relapsed and Refractory NHL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Buparlisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2013-02-28",
      "completion_date": "2017-07-21",
      "has_results": true,
      "last_update_posted_date": "2018-09-28",
      "last_synced_at": "2026-10-31T06:51:48.530Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Omaha, Nebraska • New York, New York + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01693614"
    },
    {
      "nct_id": "NCT06492304",
      "title": "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "T Cell Lymphoma",
        "B Cell Lymphoma",
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "CTX131",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CRISPR Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 12,
      "start_date": "2024-08-13",
      "completion_date": "2026-03-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-10-31T06:51:48.530Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Stanford, California • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06492304"
    },
    {
      "nct_id": "NCT02815397",
      "title": "DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2016-02",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2017-11-17",
      "last_synced_at": "2026-10-31T06:51:48.530Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02815397"
    },
    {
      "nct_id": "NCT03422679",
      "title": "Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Adenoid Cystic Carcinoma",
        "Non-hodgkin Lymphoma",
        "Glomus Tumor, Malignant",
        "Hepatocellular Carcinoma",
        "Osteosarcoma",
        "T-ALL"
      ],
      "interventions": [
        {
          "name": "CB-103",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cellestia Biotech AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2017-12-05",
      "completion_date": "2022-11-11",
      "has_results": true,
      "last_update_posted_date": "2024-01-16",
      "last_synced_at": "2026-10-31T06:51:48.530Z",
      "location_count": 3,
      "location_summary": "Santa Monica, California • Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03422679"
    },
    {
      "nct_id": "NCT04762160",
      "title": "SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Tazemetostat",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Epizyme, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2020-12-15",
      "completion_date": "2022-03-22",
      "has_results": true,
      "last_update_posted_date": "2024-03-25",
      "last_synced_at": "2026-10-31T06:51:48.530Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Fountain Valley, California • Boulder, Colorado + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Niles",
          "state": "Illinois"
        },
        {
          "city": "Rolling Meadows",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04762160"
    },
    {
      "nct_id": "NCT02243579",
      "title": "Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Mycosis Fungoides and Sezary Syndrome",
        "Refractory Mycosis Fungoides and Sezary Syndrome",
        "Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7",
        "Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7",
        "Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7",
        "Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7",
        "Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7",
        "Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7",
        "Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2014-10-15",
      "completion_date": "2019-04-01",
      "has_results": true,
      "last_update_posted_date": "2019-09-20",
      "last_synced_at": "2026-10-31T06:51:48.530Z",
      "location_count": 8,
      "location_summary": "Palo Alto, California • New Haven, Connecticut • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02243579"
    }
  ]
}